Executive Summary Engaging a contract development and manufacturing organization (CDMO) has gone from tactical cost arbitrage to board-level strategic decision. […]

The launch price of a new medicine is the most durable, highest-stakes financial decision a pharmaceutical company makes. It is

The premise sounds straightforward enough: a blockbuster biologic loses patent protection, a competitor copies it at lower cost, patients save

Section 1: The Economics Nobody Talks About Generic drugs fill roughly 90% of all U.S. prescriptions while accounting for only

A deep-dive for pharma IP teams, portfolio managers, R&D leads, and institutional investors Executive Summary The generic pharmaceutical industry is

Defining a Blockbuster Drug in 2026 — and Why the Definition Is Shifting The pharmaceutical industry has operated with a

A deep dive into patent cliffs, IP valuation, biosimilar development roadmaps, complex generics portfolios, and the regulatory playbooks that will

Part I: The Economics of Generic Entry — Why the Old Model Is Broken The Scale of the Industry and

Key Facts Before You Read Part I: The Market Paradox and Its Structural Drivers The Affordability Paradox: Why the Generic